Polymeric Drug Conjugates Modular Linker Design
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The development of targeted drug conjugates, particularly antibody-drug conjugates, is hindered by the complexity of chemical linkers, leading to a need for potent therapeutics with a high therapeutic index and efficient delivery to specific cells like tumor cells while minimizing side effects.
Innovation Solution
The development of dimeric and polymeric biologically active compounds with spacing groups, including fluorescent and colored dyes, that are covalently linked to a common backbone, allowing for selective delivery to targets such as tumor cells, and methods for their preparation and use in therapeutic treatments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If traditional chemical linkers are used in antibody-drug conjugates, then the conjugate can be manufactured, but the complexity of the construct increases significantly
Solution Approach 1:
The patent segments the ADC construct into modular components: a simplified linker backbone and separate drug payload units. The linker contains predefined reactive groups that can independently couple to antibodies or drugs, allowing the construct to be assembled from discrete, manufacturable modules rather than requiring complex integrated chemical linkers.
Solution Approach 2:
The linker backbone is designed with multiple universal reactive groups (e.g., NHS esters, maleimides, azides) that can perform multiple functions: coupling to antibody amino groups, coupling to drug payloads, or direct conjugation. This multi-functionality reduces the need for different specialized linkers for different conjugation strategies, simplifying the overall construct design.
2Object-affected harmful factors
If targeted drug conjugates are designed to deliver drugs selectively to target cells, then off-target activity is minimized, but the therapeutic index must be maximized for clinical effectiveness
Solution Approach 1:
The patent incorporates targeting moieties (such as antibody fragments, peptides, or small molecules) at specific locations on the conjugate structure that recognize and bind to receptors on target cells. This localized targeting capability ensures selective drug delivery to intended cells while maintaining high therapeutic efficacy through optimized drug-to-antibody ratios and controlled release mechanisms.
Data Source
AI summary
Compounds useful as biologically active compounds are disclosed. The compounds have the following structure (I): or a stereoisomer, tautomer or salt thereof, wherein R1, R2, R3, R4, R5, L, L1, L2, M and n are as defined herein. Methods associated with preparation and use of such compounds are also provided.